Navigation Links
Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Date:10/17/2011

hydrochloride) 43

4.2.4 Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) 44

4.2.5 Cymbalta (duloxetine hydrochloride) 44

4.2.6 Pristiq (desvenlafaxine succinate) 45

4.2.7 Symbyax (olanzapine and fluoxetine combination) 46

4.3 Key Takeaway 48

5 Depression Therapeutics - Pipeline Assessment 49

5.1 Overview 49

5.2 Strategic Pipeline Assessment 49

5.3 Depression Therapeutics Pipeline – Pipeline by Phases of Development 49

5.3.1 Depression Therapeutics – Phase III Pipeline 50

5.3.2 Depression Therapeutics – Phase II Pipeline 50

5.3.3 Depression Therapeutics – Phase I Pipeline 51

5.3.4 Depression Market – Pre-Clinical Pipeline 52

5.3.5 Technology Trends Analytic Framework 52

5.4 Depression Therapeutics Market –Pipeline by Mechanism of Action 56

5.5 Depression Therapeutics – Promising Drugs under Clinical Development 57

5.6 Molecule Profile for Promising Drugs Under Clinical Development 57

5.6.1 Lu AA21004 57

5.6.2 TC-5214 58

5.6.3 AGO178 (agomelatine) 59

5.7 Key Takeaway 60

6 Depression Therapeutics - Clinical Trials Mapping 61

6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 61

6.2 Clinical Trials by Phase 62

6.3 Clinical Trials by Trial Status 63

6.4 Prominent Sponsors 64

6.5 Top Companies Participating in Depression Therapeutics Clinical Trials 66

7 Strategic Assessment 67

7.1 Key Events Impacting the Future Market 67

7.2 Depression Therapeutics: Implications for Future Market Competition 68

8 Depression Therapeutics: Future Players 69

8.1 Introduction 69

8.2 Company Profiles 69

8.2.1 Lundbeck A/S 69

8.2.2 Novartis AG 71

8.2.3 AstraZeneca PLC 72

8.2.4 Eli Lilly and Company 74

8.2.5 Targacept Inc. 75

9 Depression Therapeutics - Licensing and Partner
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Phreesias Digital Depression Screening Improves Early Detection and Drives Better Healthcare Outcomes in Medical Practices
2. Potential Mechanism of Action Identified for the Treatment of Major Depression With Trigeminal Nerve Stimulation (TNS) - The USB Port to the Brain™
3. Reportlinker Adds Product Profiles: Depression - Next generation Vies for Second-Line Patients
4. Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression
5. Neuralstem Updates NSI-189 Major Depression Trial
6. Vanda Pharmaceuticals to Evaluate Tasimelteon in Major Depression
7. CeNeRx Initiates Phase II Trial of TriRima™ as Monotherapy in Treatment Resistant Depression
8. Neuralstem Receives FDA Approval to Commence Drug Trial for Major Depression
9. Omega-3 Supplements Show Promise in Alleviating Depression
10. The Welcome Back Awards Seeks Nominations to Honor Leaders in the Depression Community
11. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
(Date:1/15/2014)... Pharmaceuticals International, Inc. (NYSE: VRX and ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with ... indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for all ... Medical, Inc. (NASDAQ: SLTM ) ("Solta") at ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... 2011 Reportlinker.com announces that a new market research ... Pain Therapeutics - Drugs, Markets and Companies ... report describes the latest concepts of pathomechanisms of pain ... pharmacotherapies for pain. Major segments of the pain market ...
... Pharmacotherapy research is set to become vastly more ... Wolters Kluwer Pharma Solutions , parent of the ... scientific information and analytics to professionals in the pharmaceutical and ... access (OA) publishing option for authors submitting original research articles ...
Cached Medicine Technology:Reportlinker Adds Pain Therapeutics - Drugs, Markets and Companies 2Reportlinker Adds Pain Therapeutics - Drugs, Markets and Companies 3Adis Journals Embrace Open Access 2Adis Journals Embrace Open Access 3Adis Journals Embrace Open Access 4
(Date:4/24/2014)... and irrelevant, could offer an alternative to heart transplants ... Furtado, and her team from the Australian Regenerative Medicine ... fibroblast is a close relative to a cardiomyocyte, the ... research published today in Circulation Research , Dr ... due to their genetic program, and will aid in ...
(Date:4/24/2014)... national response to the epidemic of prescription opioid overdose ... Journal of Medicine by leaders of agencies in ... The commentary calls upon health care providers to expand ... reduce overdose deaths, and describes a number of misperceptions ... The commentary also discusses how medications can be used ...
(Date:4/24/2014)... It is better to give than to receive ... a new study suggests. , The study found that 15- ... giving their money to family members, are less likely to ... taking risks or keeping the money for themselves. , The ... National Academy of Sciences . , The study focused on ...
(Date:4/24/2014)... NH, 4/24/14) Dartmouth has been awarded one of ... serve as a Lead Academic Participating Site in its ... Award recipients are a select groups of investigators charged ... fewer cooperative groups., The NCTN grant system reflects recommendations ... It streamlines operations to achieve four goals:, ...
(Date:4/24/2014)... The National Science Foundation has awarded LSU ... for Undergraduates (REU) Site grant in the amount ... of undergraduates from diverse social and educational backgrounds, ... Orleans area. The project will provide students ... of 2014-16. It will be led by ...
Breaking Medicine News(10 mins):Health News:Boring cells could hold the key to heart disease 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3
... Yealink ... ... America’s leading supplier of Voice over IP (VoIP) equipment and complete systems, today announced the launch ... phones is comprised of five different SIP based models that range in price from $72 USD ...
... At The Parker Center ... surgery. , ... 2010 -- In light of recent media coverage of teens and plastic surgery, including a Today ... a great opportunity to address the right way to approach cosmetic surgery for teens and young ...
... ... Shared Hosting Servers , ... Charlotte, NC (PRWEB) May 19, 2010 -- ORCS Web Inc., a specialist in ... solutions announced that Microsoft’s newly released WCF RIA Services for Silverlight 4 has ...
... ... Participation from Amicus Capital and Prominent Angel Investors. , ... (PRWEB) May 19, 2010 -- SeniorHomes.com , ... or senior housing, announced today that it received a $1.1 million of Series A ...
... Nearly 2.5 million ... Because nearly 90% of eye injuries are preventable with proper protective eyewear, Defog It antifog ... ... Nearly 2.5 million eye injuries occur each year in the United States, with almost half occurring ...
... examining expression of every human gene in clear cell renal ... Mayo Clinic,s campus in Florida have discovered gene signatures they ... difficult-to-treat kidney cancer . In the May ... they have discovered: a biological pathway signature of ccRCC for ...
Cached Medicine News:Health News:VoIP Supply Adds Yealink IP Phones 2Health News:With the Right Approach, Plastic Surgery for Teens and Young Adults is Now a Positive Experience 2Health News:With the Right Approach, Plastic Surgery for Teens and Young Adults is Now a Positive Experience 3Health News:With the Right Approach, Plastic Surgery for Teens and Young Adults is Now a Positive Experience 4Health News:With the Right Approach, Plastic Surgery for Teens and Young Adults is Now a Positive Experience 5Health News:ORCS Web, Inc Makes Available WCF RIA Services 2Health News:SeniorHomes.com Closes $1.1 Million Series A Round of Investment Financing 2Health News:Eye Protection at Home Could Help Prevent 1 Million Home Eye Injures: Tips from Defog It Antifog During National Healthy Vision Month 2010 2Health News:Eye Protection at Home Could Help Prevent 1 Million Home Eye Injures: Tips from Defog It Antifog During National Healthy Vision Month 2010 3Health News:Mayo Clinic researchers find genetic secrets to common kidney cancer 2Health News:Mayo Clinic researchers find genetic secrets to common kidney cancer 3Health News:Mayo Clinic researchers find genetic secrets to common kidney cancer 4
The new, single-use 26 mL applicator is latex-free, hands-off and sterile to help prevent cross-contamination. The applicator is designed for a smooth delivery of the solution for larger surgical pro...
... Anti-HCV Low Titer Performance Panel consists of ... to strong positive for antibodies to the ... for use by manufacturers and diagnostic laboratories ... from all major test systems are included ...
Comprised of a monofilament polypropylene mesh coated with hydrophilic porcine collagen, Pelvitex™ mesh is clinically proven coating to enhance the healing process, along with the strength and d...
... a biological material derived from ... for excellent suppleness and strength. ... ensure high levels of quality ... enhances the biocompatibility, performance and ...
Medicine Products: